Anzeige
Mehr »
Donnerstag, 12.02.2026 - Börsentäglich über 12.000 News
Top-Ergebnisse: 1,75 g/t Gold über 30,4 Meter + massives Tagebau-Potenzial
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
302 Leser
Artikel bewerten:
(1)

Sectra takes major step toward improved cancer care--now supports all high-volume pathology scanners

LINKÖPING, Sweden, Oct. 26, 2020 /PRNewswire/ -- International medical imaging IT and cybersecurity company Sectra (STO: SECT B) is adding support for two additional file formats within digital pathology, and is now supporting all high-volume scanners for routine diagnostics. The ability for healthcare providers to select the most suitable scanner and imaging solution, without having to consider integration compatibility, allows for improved cancer care as a result of increased efficiency in primary diagnostics.

"Imaging solutions are a critical component of healthcare IT infrastructure. However, without deep integration in surrounding IT systems and support for a wide range of file formats and standards, the true clinical gains will not be realized. That is why vendor neutrality is so important, and something we strive toward across all our products. Within pathology, we have now taken an important step by pushing vendor neutrality even further. I'm convinced that this will translate into better cancer care as healthcare providers can now choose the most suitable scanner for their specific workflow," says Elin Kindberg, Global Product Manager of Pathology at Sectra.

With digital images of tissue samples instead of physical glass slides, pathologists are able to instantly access and share current and historical images and information between departments and hospitals. This digital solution provides pathologists with assistance at critical decision points, such as grading or performing more precise measurements. Sectra's digital pathology solution also allows integrated diagnostics-a flow of information across departmental borders for better collaboration and clinical decisions.

Sectra has for many years been in the forefront in pushing vendor neutrality to support adoption of digital pathology in clinical routine practice, and already supports DICOM for pathology images. Since digital pathology is still an emerging technology, not all scanner vendors produce images in a standard file format, instead using so-called proprietary file formats. Sectra supports several of these already, but now, with the extension of the additional two file formats, Sectra supports all high-volume pathology scanners. This provides healthcare providers with full freedom of choice when choosing scanners.

Sectra's digital pathology module is being used in primary diagnostics on several markets and received FDA approval in the US in March 2020. During the COVID-19 pandemic, the FDA has also allowed remote digital diagnostics and US labs can use any scanner during this enforcement policy. Under normal circumstances, Sectra's digital pathology solution has FDA approval for primary diagnostics when used together with Leica Biosystems' AT2 DX scanner and the Dell MR2416 monitor. Sectra's solution for digital pathology is part of Sectra's enterprise imaging solution and provides a unified strategy for all imaging needs. The scalable and modular solution, with a VNA at its core, allows healthcare providers to grow from ology to ology and from enterprise to enterprise. Read more about Sectra's enterprise imaging solution and why Sectra PACS is ranked "Best in KLAS" for seven consecutive years at medical.sectra.com.

About Sectra
Sectra assists hospitals throughout the world to enhance the efficiency of care, and authorities and defense forces in Europe to protect society's most sensitive information. Thereby, Sectra contributes to a healthier and safer society. The company was founded in 1978, has its head office in Linköping, Sweden, with direct sales in 19 countries, and operates through partners worldwide. Sales in the 2019/2020 fiscal year totaled SEK 1,661 million. The Sectra share is quoted on the Nasdaq Stockholm exchange. For more information, visit https://sectra.com/.

CONTACT:

For further information, please contact:
Dr. Torbjörn Kronander, CEO and President Sectra AB, 46-(0)-705-23-52-27
Marie Ekström Trägårdh, Executive Vice President Sectra AB and President Sectra Imaging IT Solutions, 46-(0)708-23-56-10

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/sectra/r/sectra-takes-major-step-toward-improved-cancer-care-now-supports-all-high-volume-pathology-scanners,c3222189

The following files are available for download:

https://news.cision.com/sectra/i/sectra-digital-pathology,c2843104

Sectra Digital Pathology

© 2020 PR Newswire
Favoritenwechsel
Das Börsenjahr 2026 ist für viele Anleger ernüchternd gestartet. Tech-Werte straucheln, der Nasdaq 100 tritt auf der Stelle und ausgerechnet alte Favoriten wie Microsoft und SAP rutschen zweistellig ab. KI ist plötzlich kein Rückenwind mehr, sondern ein Belastungsfaktor, weil Investoren beginnen, die finanzielle Nachhaltigkeit zu hinterfragen.

Gleichzeitig vollzieht sich an der Wall Street ein lautloser Favoritenwechsel. Während viele auf Wachstum setzen, feiern Value-Titel mit verlässlichen Cashflows ihr Comeback: Telekommunikation, Industrie, Energie, Pharma – die „Cashmaschinen“ der Realwirtschaft verdrängen hoch bewertete Hoffnungsträger.

In unserem aktuellen Spezialreport stellen wir fünf Aktien vor, die genau in dieses neue Marktbild passen: solide, günstig bewertet und mit attraktiver Dividende. Werte, die nicht nur laufende Erträge liefern, sondern auch bei Marktkorrekturen Sicherheit bieten.

Jetzt den kostenlosen Report sichern – bevor der Value-Zug 2026 endgültig abfährt!

Dieses exklusive PDF ist nur für kurze Zeit gratis verfügbar.
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.